Our practice uses a topical immunomodulator to treat actinic keratosis. Would it be correct to report the 17000 , 17003 and 17004 code series for this service? ...
Subscribe or sign in to view the full article.
Article Overview
This short coding advisory explains a question about reporting procedure codes for actinic keratosis treatment when a topical immunomodulator is used. It is relevant to medical coders, billers, and dermatology practices that need general guidance on how this type of service is discussed in relation to destruction-based procedure coding.
Why This Topic Matters
Understanding the scope of this article helps users quickly determine whether it addresses coding for non-destructive topical treatment versus destruction-based lesion management in dermatology.
What You Will Learn
- The article’s focus in relation to actinic keratosis treatment coding
- How the topic is framed around topical therapy versus lesion destruction
- Which general procedure-code area the advisory discusses
- The type of coding question the article is meant to clarify
Who Should Read This
- Medical coders
- Medical billers
- Dermatology practices
- Coding auditors
- Revenue cycle staff
Codes Discussed
Code Ranges Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com